Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD2 | Q9Y5L3 | 3/20 | 0.85 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.82 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384425 | 1.00 | ENTPD2 (0.85) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL13210969 | 0.92 | ENTPD2 (1.00) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL14384565 | 0.92 | ENTPD2 (1.00) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL13210974 | 0.90 | ENTPD1 (1.00) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL13210975 | 0.89 | ENTPD1 (0.91) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL3019591 | 0.87 | ENTPD2 (0.65) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL3019597 | 0.87 | ENTPD2 (0.65) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL5277178 | 0.85 | ENTPD2 (0.68) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL5284532 | 0.81 | ENTPD2 (0.76) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 | |
| SCHEMBL13210978 | 0.80 | ENTPD2 (1.00) | ENTPD2ENTPD1P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| WO-2007135195-A1 | ECTONUCLEOTIDASE INHIBITORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-29 | — | — | WO | disclosed |
| EP-1860113-A1 | Ectonucleotidase inhibitors | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ENTPD2 10/4885ENTPD1 3/4885P2RY6 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.